Trial · NCT01702571
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events of Primary Interest (AEPIs) | Trastuzumab Emtansine (All Participants) | 23.1 | 95% Confidence Interval 21.2 to 25.0 | Percentage of Participants | |
| Percentage of Participants With Adverse Events of Primary Interest (AEPIs) | Trastuzumab Emtansine (Asian Participants) | 51.4 | 95% Confidence Interval 43.9 to 58.9 | Percentage of Participants | |
| Percentage of Participants With Specific AEPIs | Trastuzumab Emtansine (All Participants) | AEs Grade >/= 3 for hepatic events | 6.9 | Percentage of Participants | |
| Percentage of Participants With Specific AEPIs | Trastuzumab Emtansine (Asian Participants) | AEs Grade >/= 3 for hepatic events | 12.2 | Percentage of Participants | |
| Percentage of Participants With Specific AEPIs | Trastuzumab Emtansine (All Participants) | AEs Grade >/= 3 for allergic reactions | 2.3 | Percentage of Participants | |
| Percentage of Participants With Specific AEPIs | Trastuzumab Emtansine (Asian Participants) | AEs Grade >/= 3 for allergic reactions | 1.1 | Percentage of Participants | |
| Percentage of Participants With Specific AEPIs | Trastuzumab Emtansine (All Participants) | AEs Grade >/= 3 for thrombocytopenia | 3.7 | Percentage of Participants | |
| Percentage of Participants With Specific AEPIs | Trastuzumab Emtansine (Asian Participants) | AEs Grade >/= 3 for thrombocytopenia | 36.5 | Percentage of Participants | |
| Percentage of Participants With Specific AEPIs | Trastuzumab Emtansine (All Participants) | AEs Grade >/= 3 for hemorrhage events | 2.3 | Percentage of Participants | |
| Percentage of Participants With Specific AEPIs | Trastuzumab Emtansine (Asian Participants) | AEs Grade >/= 3 for hemorrhage events | 1.7 | Percentage of Participants | |
| Percentage of Participants With Specific AEPIs | Trastuzumab Emtansine (All Participants) | AEs Grade >/= 3 related to trastuzumab emtansine | 18.4 | Percentage of Participants | |
| Percentage of Participants With Specific AEPIs | Trastuzumab Emtansine (Asian Participants) | AEs Grade >/= 3 related to trastuzumab emtansine | 48.6 | Percentage of Participants | |
| Percentage of Participants With Specific AEPIs | Trastuzumab Emtansine (All Participants) | Pneumonitis of all grades | 1.0 | Percentage of Participants | |
| Percentage of Participants With Specific AEPIs | Trastuzumab Emtansine (Asian Participants) | Pneumonitis of all grades | 2.2 | Percentage of Participants | |
| Percentage of Participants With Adverse Events of Special Interest (AESIs) | Trastuzumab Emtansine (All Participants) | Potential drug-induced liver injury | 1.2 | Percentage of Participants | |
| Percentage of Participants With Adverse Events of Special Interest (AESIs) | Trastuzumab Emtansine (Asian Participants) | Potential drug-induced liver injury | 1.1 | Percentage of Participants | |
| Percentage of Participants With Adverse Events of Special Interest (AESIs) | Trastuzumab Emtansine (All Participants) | Suspected transmission of an infectious agent | 0.2 | Percentage of Participants | |
| Percentage of Participants With Adverse Events of Special Interest (AESIs) | Trastuzumab Emtansine (Asian Participants) | Suspected transmission of an infectious agent | 0.0 | Percentage of Participants | |
| Progression-Free Survival According to Response Evaluation for Solid Tumors (RECIST) Version (v) 1.1 As Per Investigator Assessment | Trastuzumab Emtansine (All Participants) | 6.8 | 95% Confidence Interval 5.8 to 7.6 | months | |
| Progression-Free Survival According to Response Evaluation for Solid Tumors (RECIST) Version (v) 1.1 As Per Investigator Assessment | Trastuzumab Emtansine (Asian Participants) | 5.7 | 95% Confidence Interval 5.5 to 7.0 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01702571/results